Immunomedics (IMMU) 4.58 $IMMU
Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of Sacituzumab Govitecan (Immu-132) in Patients With Advanced Triple-Negative Breast Cancer
GlobeNewswire - Fri Dec 12, 9:02AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's novel investigational antibody-drug conjugate (ADC), continues to produce a partial response (PR) rate of 30% and a 70% clinical benefit rate (CBR), defined as PR and stable disease, in patients with metastatic triple-negative breast cancer (TNBC) who had been heavily pretreated. For patients with PR or stable disease longer than 6 months, the CBR was 40%. Significantly, PRs ranging from 30% to 70% tumor shrinkage as best response were reported. Responses are measured by computed tomography (CT) based on RECIST 1.1 criteria.
IMMU: 4.58 (-0.09)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), TGTX: 18.25 (+0.74), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), AZN: 71.80 (-1.80), ABBV: 65.27 (-1.76), INFI: 17.78 (-0.21), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.94 (+0.74), BIIB: 344.49 (+2.16), IMMU: 4.58 (-0.09), RDHL: 12.98 (+0.80), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), ARGS: 8.34 (unch), NVO: 44.48 (-1.14), IDRA: 3.84 (-0.03), ANTH: 2.05 (+0.08), MRK: 57.72 (-1.62), CBMG: 14.10 (+0.12), CELGZ: 3.51 (-0.03)
Immunomedics to Present at 25th Annual Oppenheimer Healthcare Conference
GlobeNewswire - Thu Dec 04, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at the 25 Annual Oppenheimer Healthcare Conference on Wednesday, December 10 at 8:00 a.m. Eastern Time at the Crowne Plaza Hotel in New York City. The presentation, which provides a corporate overview, can be downloaded simultaneously at http://www.immunomedics.com/pdfs/company-presentation.pdf.
IMMU: 4.58 (-0.09)
Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders
GlobeNewswire - Wed Dec 03, 12:00PM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that stockholders of the Company have approved all the matters submitted to them at the Company's Annual Meeting of Stockholders held at 10:00 a.m., Eastern Time, on Wednesday, December 3, 2014.
IMMU: 4.58 (-0.09)
Lung Adenocarcinoma - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/c2qszp/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Astex Pharmaceuticals - AstraZeneca - Axelar - Bayer - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Genentech - Genmab - Hanmi Pharmaceuticals - Immunomedics - Medisyn Technologies - Pfizer - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/c2qszp/lung
IMMU: 4.58 (-0.09), AMGN: 164.53 (-1.55)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.58 (-0.09), AMGN: 164.53 (-1.55), RGLS: 16.06 (-0.25), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), PVCT: 0.89 (unch), CANF: 3.49 (+0.03), DCTH: 1.27 (+0.03), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29)
Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 344.49 (+2.16), IMMU: 4.58 (-0.09)
Immunomedics humanized antibody tagged an Orphan Drug for rare autoimmune disease
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:52AM CST
IMMU: 4.58 (-0.09)
Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus
GlobeNewswire - Fri Nov 21, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the Company's humanized anti-CD20 antibody, for the treatment of pemphigus.
IMMU: 4.58 (-0.09)
Immunomedics Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy
GlobeNewswire - Thu Nov 20, 9:11AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that Dr. David M. Goldenberg, Chairman, Chief Scientific Officer and Chief Medical Officer, presented a plenary session talk entitled, "Challenging the Dogmas: Clinical Efficacy of SN-38-Conjugated Antibodies in Solid Tumors," at the joint symposium of the European Organization for the Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). In his lecture, Dr. Goldenberg differentiated the Company's antibody-drug conjugate (ADC) platform technology from other technologies.
IMMU: 4.58 (-0.09)
Global Antibody Drug Conjugate Market Outlook 2018 Edition
M2 - Fri Nov 14, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/m3rq9c/global_antibody) has announced the addition of the "Global Antibody Drug Conjugate Market Outlook 2018 Edition" report to their offering. According to our report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC market is anticipated to reach around US$ 3 Billion by 2018. For more than a century, the concept of a magic bullet to deliver cytotoxic therapy to the site of tumor has been envisioned, but only recently the technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of ADCETRIS and Kadcyla followed by various ADCs in pipeline highlight the potential for new therapeutic innovations in ADC industry. The report also provides an insight into the key ADCs that are in advanced stage of trial, with Glembatumumab vedotin (Anti-GPNMB ADC) as one of the examples. Further, the report highlights the ADCs with respect to the type of cancer targeted, and drugs used. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place in the ADC space have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones, for the development of ADCs. Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs, difficult upstream and downstream processing, safety considerations, etc., will have to be taken care of. At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Antibody Drug Conjugate (ADC) - An Introduction 4. ADC Market Outlook to 2018 5. ADC Pipeline Analysis 6. Current Status of Potential ADCs in Pipeline 7. Strategic Collaborations in the ADC Industry 8. Drivers and Challenges 9. Competitive Landscape Companies Mentioned - Agensys, Inc. - Immunogen, Inc. - Immunomedics - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/m3...l_antibody
IMMU: 4.58 (-0.09), IMGN: 10.01 (unch)
Immunomedics Announces Six Presentations on Epratuzumab in Lupus at Leading Rheumatology Meeting
GlobeNewswire - Fri Nov 14, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that partner UCB, S.A., responsible for the development of epratuzumab in non-oncology indications, is sponsoring 6 presentations on investigational studies of epratuzumab in systemic lupus erythematosus (SLE) at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, November 14 - 19, 2014 in Boston, MA.
IMMU: 4.58 (-0.09)
Immunomedics' (IMMU) CEO Cynthia Sullivan on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 1:36PM CST
IMMU: 4.58 (-0.09)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.09 (+0.09), CRIS: 1.18 (+0.03), IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), ONCY: 0.61 (+0.03), PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), SNTA: 2.87 (+0.04), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29), ARRY: 4.86 (-0.04), CELGZ: 3.51 (-0.03), EXEL: 1.40 (unch)
Immunomedics Receives Third Edison Patent Award From Research & Development Council of New Jersey
GlobeNewswire - Fri Nov 07, 7:38AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company was honored by the Research & Development Council of New Jersey with their coveted Edison Patent Award, in recognition of the Company's significant achievements in the biotechnology category for its novel linker technology in building paradigm-changing antibody-drug conjugates (ADCs).
IMMU: 4.58 (-0.09)
Hot Stock: Immunomedics, Shares Drop 9.1% (IMMU)
Comtex SmarTrend(R) - Thu Nov 06, 10:37AM CST
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 9.1% to $3.38 on 1.0x average daily volume. Immunomedics has traded 878,000 shares thus far today, vs. average volume of 843,000 shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.7%) and underperformed the S&P 500 (-9.1% to the S&P's 0.5%) during today's trading.
IMMU: 4.58 (-0.09)
Immunomedics (IMMU) Weak On High Volume
at The Street - Thu Nov 06, 9:02AM CST
Trade-Ideas LLC identified Immunomedics (IMMU) as a weak on high relative volume candidate
IMMU: 4.58 (-0.09)
Immunomedics posts 1Q loss
Automated Insights - Wed Nov 05, 5:16PM CST
MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $12.4 million, or 13 cents per share, in its fiscal first quarter.
IMMU: 4.58 (-0.09)
Immunomedics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:47PM CST
IMMU: 4.58 (-0.09)
Immunomedics Reports Expanded Phase 1/2 Trials Confirm Activity and Good Safety Profile of Sacituzumab Govitecan (Immu-132) in Patients With Advanced Triple-Negative Breast Cancer
GlobeNewswire - Fri Dec 12, 9:02AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's novel investigational antibody-drug conjugate (ADC), continues to produce a partial response (PR) rate of 30% and a 70% clinical benefit rate (CBR), defined as PR and stable disease, in patients with metastatic triple-negative breast cancer (TNBC) who had been heavily pretreated. For patients with PR or stable disease longer than 6 months, the CBR was 40%. Significantly, PRs ranging from 30% to 70% tumor shrinkage as best response were reported. Responses are measured by computed tomography (CT) based on RECIST 1.1 criteria.
IMMU: 4.58 (-0.09)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), TGTX: 18.25 (+0.74), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), AZN: 71.80 (-1.80), ABBV: 65.27 (-1.76), INFI: 17.78 (-0.21), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.94 (+0.74), BIIB: 344.49 (+2.16), IMMU: 4.58 (-0.09), RDHL: 12.98 (+0.80), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), ARGS: 8.34 (unch), NVO: 44.48 (-1.14), IDRA: 3.84 (-0.03), ANTH: 2.05 (+0.08), MRK: 57.72 (-1.62), CBMG: 14.10 (+0.12), CELGZ: 3.51 (-0.03)
Immunomedics to Present at 25th Annual Oppenheimer Healthcare Conference
GlobeNewswire - Thu Dec 04, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at the 25 Annual Oppenheimer Healthcare Conference on Wednesday, December 10 at 8:00 a.m. Eastern Time at the Crowne Plaza Hotel in New York City. The presentation, which provides a corporate overview, can be downloaded simultaneously at http://www.immunomedics.com/pdfs/company-presentation.pdf.
IMMU: 4.58 (-0.09)
Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders
GlobeNewswire - Wed Dec 03, 12:00PM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that stockholders of the Company have approved all the matters submitted to them at the Company's Annual Meeting of Stockholders held at 10:00 a.m., Eastern Time, on Wednesday, December 3, 2014.
IMMU: 4.58 (-0.09)
Lung Adenocarcinoma - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/c2qszp/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Astex Pharmaceuticals - AstraZeneca - Axelar - Bayer - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Genentech - Genmab - Hanmi Pharmaceuticals - Immunomedics - Medisyn Technologies - Pfizer - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/c2qszp/lung
IMMU: 4.58 (-0.09), AMGN: 164.53 (-1.55)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.58 (-0.09), AMGN: 164.53 (-1.55), RGLS: 16.06 (-0.25), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), PVCT: 0.89 (unch), CANF: 3.49 (+0.03), DCTH: 1.27 (+0.03), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29)
Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 344.49 (+2.16), IMMU: 4.58 (-0.09)
Immunomedics humanized antibody tagged an Orphan Drug for rare autoimmune disease
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:52AM CST
IMMU: 4.58 (-0.09)
Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus
GlobeNewswire - Fri Nov 21, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the Company's humanized anti-CD20 antibody, for the treatment of pemphigus.
IMMU: 4.58 (-0.09)
Immunomedics Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy
GlobeNewswire - Thu Nov 20, 9:11AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that Dr. David M. Goldenberg, Chairman, Chief Scientific Officer and Chief Medical Officer, presented a plenary session talk entitled, "Challenging the Dogmas: Clinical Efficacy of SN-38-Conjugated Antibodies in Solid Tumors," at the joint symposium of the European Organization for the Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). In his lecture, Dr. Goldenberg differentiated the Company's antibody-drug conjugate (ADC) platform technology from other technologies.
IMMU: 4.58 (-0.09)
Global Antibody Drug Conjugate Market Outlook 2018 Edition
M2 - Fri Nov 14, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/m3rq9c/global_antibody) has announced the addition of the "Global Antibody Drug Conjugate Market Outlook 2018 Edition" report to their offering. According to our report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC market is anticipated to reach around US$ 3 Billion by 2018. For more than a century, the concept of a magic bullet to deliver cytotoxic therapy to the site of tumor has been envisioned, but only recently the technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of ADCETRIS and Kadcyla followed by various ADCs in pipeline highlight the potential for new therapeutic innovations in ADC industry. The report also provides an insight into the key ADCs that are in advanced stage of trial, with Glembatumumab vedotin (Anti-GPNMB ADC) as one of the examples. Further, the report highlights the ADCs with respect to the type of cancer targeted, and drugs used. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place in the ADC space have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones, for the development of ADCs. Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs, difficult upstream and downstream processing, safety considerations, etc., will have to be taken care of. At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Antibody Drug Conjugate (ADC) - An Introduction 4. ADC Market Outlook to 2018 5. ADC Pipeline Analysis 6. Current Status of Potential ADCs in Pipeline 7. Strategic Collaborations in the ADC Industry 8. Drivers and Challenges 9. Competitive Landscape Companies Mentioned - Agensys, Inc. - Immunogen, Inc. - Immunomedics - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/m3...l_antibody
IMMU: 4.58 (-0.09), IMGN: 10.01 (unch)
Immunomedics Announces Six Presentations on Epratuzumab in Lupus at Leading Rheumatology Meeting
GlobeNewswire - Fri Nov 14, 7:30AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that partner UCB, S.A., responsible for the development of epratuzumab in non-oncology indications, is sponsoring 6 presentations on investigational studies of epratuzumab in systemic lupus erythematosus (SLE) at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, November 14 - 19, 2014 in Boston, MA.
IMMU: 4.58 (-0.09)
Immunomedics' (IMMU) CEO Cynthia Sullivan on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 1:36PM CST
IMMU: 4.58 (-0.09)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.09 (+0.09), CRIS: 1.18 (+0.03), IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), ONCY: 0.61 (+0.03), PFE: 30.95 (-0.70), LLY: 69.55 (-2.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), JNJ: 104.43 (-2.29), SNTA: 2.87 (+0.04), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29), ARRY: 4.86 (-0.04), CELGZ: 3.51 (-0.03), EXEL: 1.40 (unch)
Immunomedics Receives Third Edison Patent Award From Research & Development Council of New Jersey
GlobeNewswire - Fri Nov 07, 7:38AM CST
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company was honored by the Research & Development Council of New Jersey with their coveted Edison Patent Award, in recognition of the Company's significant achievements in the biotechnology category for its novel linker technology in building paradigm-changing antibody-drug conjugates (ADCs).
IMMU: 4.58 (-0.09)
Hot Stock: Immunomedics, Shares Drop 9.1% (IMMU)
Comtex SmarTrend(R) - Thu Nov 06, 10:37AM CST
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 9.1% to $3.38 on 1.0x average daily volume. Immunomedics has traded 878,000 shares thus far today, vs. average volume of 843,000 shares per day. The stock has underperformed the Dow (-9.1% to the Dow's 0.7%) and underperformed the S&P 500 (-9.1% to the S&P's 0.5%) during today's trading.
IMMU: 4.58 (-0.09)
Immunomedics (IMMU) Weak On High Volume
at The Street - Thu Nov 06, 9:02AM CST
Trade-Ideas LLC identified Immunomedics (IMMU) as a weak on high relative volume candidate
IMMU: 4.58 (-0.09)
Immunomedics posts 1Q loss
Automated Insights - Wed Nov 05, 5:16PM CST
MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $12.4 million, or 13 cents per share, in its fiscal first quarter.
IMMU: 4.58 (-0.09)
Immunomedics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:47PM CST
IMMU: 4.58 (-0.09)
